VANGUARD CPV

Authorised

- Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:
VANGUARD CPV

Active substance:
Canine parvovirus, strain NL-35-D, Live

Target species:
Dog

Route of administration:
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:
Canine parvovirus, strain NL-35-D, Live
7.00 log10 50% cell culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Dog**
  - Unspecified. 0 day

Subcutaneous use:

- **Dog**
  - Unspecified. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Italy

Available in:
Italy

Package description:
Available only in Italian
Available only in Italian
Available only in Italian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Italia S.r.l

Marketing authorisation date:
13/03/1995

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Ministry Of Health

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
13/03/1995

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.